research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
Search
for
Sort by
Research
900-930 / 1000+ results research BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Re-Densification Effect of Pressure-Injected Peptide-Hyaluronic Acid Combination on Male Androgenic Alopecia
Injecting a peptide-hyaluronic acid mix improved hair growth in men with hair loss and was safe.
research - Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.
research Immunomodulators in the treatment of cutaneous lymphoma
Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia—A randomized controlled trial
Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Novel recombinant human acid α-glucosidase with optimal glycosylation is significantly better than standard of care enzyme replacement for glycogen clearance in skeletal muscles of GAA knock-out mice
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Dual-phase release finasteride-loaded microspheres for androgenetic alopecia treatment: rapid intervention and sustained control of dihydrotestosterone
A new finasteride treatment may quickly and effectively promote hair regrowth.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Th1/Th2 PB balance and CD200 expression of patients with active severe alopecia areata
Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.
research Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China
Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
Ebastine may help regrow hair in alopecia areata patients.
research Follicular delivery of a novel peptide therapeutic for the treatment of androgenic alopecia
A new peptide, murikal/SPR4, was found to significantly increase hair growth in mice, and its liposomal topical formulations enhanced hair growth more than commercial products. However, results on human scalp skin were unclear, needing more tests.
research Oral Tofacitinib for Refractory Lichen Planus Pigmentosus Coexisting with Frontal Fibrosing Alopecia
Tofacitinib significantly improved skin and hair conditions without side effects.
research 034 Characterization of novel TMEM173 mutation causing a lupus- and SAVI-like phenotype, modified by polymorphisms in TMEM173 and IFIH1
A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
research An unusual anatomical colocalization of alopecia areata and vitiligo in a child, and improvement during treatment with topical prostaglandin E2
Topical prostaglandin E2 can help treat both alopecia areata and vitiligo.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
Type I interferons may help treat skin issues in lupus and dermatomyositis.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: a comparative study
Platelet rich plasma is as effective as triamcinolone for treating alopecia areata.